In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Alicia Algeciras-Schimnich, Ph.D., a professor of laboratory medicine and pathology at Mayo Clinic and co-director of the Clinical Immunoassay Laboratory. They discuss Mayo Clinic’s plasma test for detecting Alzheimer’s disease and how it supports increased access and early detection. 

Specific topics of discussion include:

• The phospho-Tau 217 plasma test (Mayo ID: PT217) used to evaluate individuals aged 50 years and older with symptoms of cognitive impairment who are being assessed for Alzheimer’s disease and other causes of cognitive decline.
• The benefits of a blood test versus the other diagnostic methods for Alzheimer’s disease.
• Why early diagnosis is so important for quality of life and treatment planning.
• How tests like Mayo Clinic Laboratories’ PT217 may change the landscape of Alzheimer's research and treatment.